Anterior cranial fossa meningioma is a usually benign brain tumor that grows from the lining of the brain at the front of the skull base. People with anterior cranial fossa meningioma may notice headaches, changes in smell, memory or personality shifts, or vision problems, and doctors may see swelling of the optic nerves or subtle cognitive changes on exam. It often grows slowly over years, and many are found in midlife or later, but it can be recognized at any adult age. Treatment commonly includes careful MRI monitoring, surgery to remove the tumor, and sometimes focused radiation, and many people do well with treatment. The outlook is generally good because most tumors are noncancerous, but risks depend on size, location near nerves and blood vessels, and overall health.
Overview
Anterior cranial fossa meningiomaSymptoms
Anterior cranial fossa meningioma often causes dull headaches, personality or behavior changes, and reduced sense of smell. Some develop blurred vision, memory trouble, or seizures. Early symptoms of anterior cranial fossa meningioma can be subtle, like apathy or poor concentration.
Outlook and prognosis
Many people with anterior cranial fossa meningioma do well, especially when tumors are small, slow-growing, and found early. Surgery often controls the tumor, sometimes with focused radiation for remnants or regrowth. Long-term follow-up imaging helps maintain vision, smell, and cognitive function.
Causes and risk factors
Anterior cranial fossa meningioma usually arises from spontaneous DNA changes in meningeal cells; rarely from inherited conditions like neurofibromatosis type 2. Risk increases with prior head radiation, female sex and hormones, older age, and possibly obesity.
Genetic influences
Genetics play a modest role in anterior cranial fossa meningioma overall, but certain inherited syndromes, like neurofibromatosis type 2, raise risk. Tumor DNA changes—often NF2 or other pathway alterations—can guide prognosis and, sometimes, targeted therapy choices.
Diagnosis
Doctors suspect anterior cranial fossa meningioma based on symptoms and a neurological exam. The diagnosis of anterior cranial fossa meningioma is made with brain MRI with contrast (and sometimes CT); tissue from surgery or biopsy confirms it under the microscope.
Treatment and drugs
Treatment for anterior cranial fossa meningioma is tailored to tumor size, location, symptoms, and growth rate. Options often include careful MRI monitoring, microsurgical removal, and focused radiation (such as stereotactic radiosurgery) when surgery is risky or for residual tumor. Care teams also manage headaches, seizures, swelling, and vision or smell changes with medicines and rehabilitation.
Symptoms
Anterior cranial fossa meningioma can cause slow, subtle changes in daily life, often tied to the forehead part of the brain that handles thinking, smell, and vision. Early symptoms of anterior cranial fossa meningioma may include headaches, a weaker sense of smell, or small shifts in mood or personality. Symptoms vary from person to person and can change over time. As pressure builds, other issues like vision problems, seizures, or nausea can appear.
Dull pressure in the forehead or behind the eyes can build over time. Morning pain or pain that worsens with bending over is common in anterior cranial fossa meningioma.
Scents seem faint or missing, and favorite foods may taste bland. You might realize you can’t smell coffee or perfume like before. This often happens when anterior cranial fossa meningioma presses on the smell pathways.
Apathy, irritability, or saying things without the usual filter can creep in. Friends or family may notice a shift before you do. This can be an effect of anterior cranial fossa meningioma on the frontal part of the brain.
Short-term memory slips, slower thinking, or trouble planning can appear. Bills, appointments, or multi-step tasks may take extra effort.
How people usually first notice Anterior cranial fossa meningioma?
People usually first notice an anterior cranial fossa meningioma through slow, subtle changes rather than sudden symptoms. Early clues can include new or worsening headaches, changes in smell or taste, personality or behavior shifts, trouble concentrating, or vision changes like blurriness or double vision; family or coworkers may spot these mood or thinking changes before the person does. Many are discovered incidentally on brain imaging done for headaches, minor head injury, or other reasons, which is often how the first signs of anterior cranial fossa meningioma come to light.
Types of Anterior cranial fossa meningioma
Anterior cranial fossa meningioma can affect daily life in different ways depending on where the tumor sits and which nearby structures it presses on. Some people notice changes in smell or personality, while others have headaches, vision issues, or seizures. Clinicians often describe them in these categories: tumors centered at the planum sphenoidale, olfactory groove, or tuberculum sellae, and less commonly along the cribriform plate or frontopolar regions. Understanding the main types of anterior cranial fossa meningioma helps explain why symptoms differ and can guide which tests and treatments are recommended.
Olfactory groove
Often causes reduced or lost sense of smell and subtle personality or behavior changes. Headaches and pressure behind the forehead are common as the tumor grows. Early symptoms of anterior cranial fossa meningioma here can be easy to miss.
Planum sphenoidale
Frequently leads to gradually worsening vision, especially side vision, by compressing the optic nerves. Headaches and a sense of nasal congestion without infection may occur. Some may notice changes in smell as well.
Tuberculum sellae
Tends to cause visual loss or blurring and difficulty with peripheral vision from pressure on the optic chiasm. Eye exam may show optic nerve pallor over time. Timely care can help protect remaining vision.
Cribriform plate
Smell loss is common, sometimes with a clear watery nasal drip if skull base bone is thinned. People may have frontal headaches and a feeling of sinus pressure. Seizures can occur but are less common.
Frontopolar/parasagittal
Can present with attention or executive function changes and new-onset seizures. Weakness or numbness in a leg may appear if the tumor approaches the midline motor areas. Headaches often fluctuate in intensity.
What genetics can tell you about symptoms
Certain NF2 gene changes can lead to multiple anterior cranial fossa meningiomas that cause headaches, smell or vision changes, seizures, or personality shifts by pressing on the frontal lobes. TRAF7 or KLF4 variants are often linked to skull-base tumors causing gradual vision loss or eye movement problems.
Causes and risk factors
Anterior cranial fossa meningioma often starts when cells in the brain’s covering acquire DNA changes and keep growing. Key risk factors for anterior cranial fossa meningioma include prior head or neck radiation, older age, and higher body weight. Women are affected more often, and hormones in pregnancy or some hormone therapies may influence growth. Most cases are not inherited, but a family history or a rare disorder called neurofibromatosis type 2 can raise risk. Doctors distinguish between risk factors you can change and those you can’t.
Environmental and biological risk factors
Knowing what can raise the chance of an anterior cranial fossa meningioma helps you and your care team plan monitoring and limit avoidable exposures. Doctors often group risks into internal (biological) and external (environmental). If you’re reading about early symptoms of anterior cranial fossa meningioma, it’s also useful to understand the main biological and environmental risks. Below are key factors supported by research.
Meningiomas happen more often in middle-aged and older adults. This pattern also applies to tumors at the front of the skull base.
People assigned female at birth are more likely to develop meningiomas. Hormone-sensitive cells in the meninges may respond to natural sex hormones like progesterone. This may raise the chance of an anterior cranial fossa meningioma over a lifetime.
Past high-dose radiation to the head or neck, especially during childhood cancer therapy, can increase risk years later. This includes older radiation treatments that used higher doses than today. Typical diagnostic imaging uses far lower doses and is not considered a major driver of risk.
Long-term use of certain high-dose progestin medications has been linked to meningiomas, often at the skull base. The risk appears to rise with larger cumulative doses and longer exposure. This has included anterior cranial fossa meningioma in some reports.
Genetic risk factors
Anterior cranial fossa meningioma often arises from specific gene changes within the tumor, and certain changes are especially common at the skull base. A smaller number of people have inherited conditions that increase the chance of multiple or earlier meningiomas. Carrying a genetic change doesn’t guarantee the condition will appear. Here’s what is known about genetic risk factors for anterior cranial fossa meningioma.
SMO mutations: Changes in the SMO gene are enriched in meningiomas along the anterior skull base, a common site for anterior cranial fossa meningioma. These tumor-acquired changes switch on a growth signal that helps the tumor form. They are typically seen in slow-growing, non-NF2 tumors.
AKT1 mutations: Alterations in AKT1 are frequent in skull base tumors and are found in some anterior cranial fossa meningioma. These are changes within the tumor that activate a cell-growth pathway. Mosaic AKT1 changes in Proteus syndrome can also raise lifetime risk.
KLF4 + TRAF7: This co-mutation pattern is characteristic of secretory meningiomas, often arising at the skull base. It usually reflects a tumor-acquired change rather than something inherited. These tumors are commonly slow-growing.
POLR2A mutations: Changes in POLR2A occur in a subset of skull base meningiomas, including tumors near the tuberculum sellae in the anterior cranial fossa. They are somatic changes and often linked with slow-growing tumors.
PIK3CA mutations: Some skull base tumors, sometimes including anterior cranial fossa meningioma, carry PIK3CA changes. These activate a cell-growth pathway inside the tumor. They are not usually inherited.
Chromosome 22/NF2 loss: Loss of the NF2 gene on chromosome 22 drives many meningiomas across locations. It is less common in anterior skull base tumors but can still occur. This change typically happens in the tumor cells and is not inherited.
NF2 syndrome: An inherited NF2 gene change (neurofibromatosis type 2) greatly increases the chance of multiple meningiomas, including those at the skull base. People with this condition may develop anterior cranial fossa meningioma at younger ages. Family members can be at risk too.
PTEN (Cowden) syndrome: PTEN hamartoma tumor syndrome is an inherited condition that raises the chance of meningioma. Anterior skull base tumors can occur, though risk varies between families. A detailed family history can help spot this pattern.
SMARCE1 variants: Inherited changes in SMARCE1 predispose to clear cell meningioma, often in younger people. While spinal and posterior fossa tumors are more typical, cranial tumors can also happen. Families may see cases across generations.
SMARCB1 variants: Germline SMARCB1 changes are linked to multiple meningiomas and schwannomas in some families. Tumors can include skull base and anterior cranial fossa meningioma. Not everyone with the change will develop tumors.
BAP1 syndrome: Inherited BAP1 changes can lead to more aggressive meningiomas with specific features. Risk includes intracranial tumors that may behave less predictably. Other cancers can also be part of this syndrome.
Lifestyle risk factors
Research on lifestyle risk factors for anterior cranial fossa meningioma largely mirrors data for meningiomas overall. The most consistent signals involve body weight and exposure to exogenous hormones, while regular physical activity may be protective. Below are the lifestyle risk factors for anterior cranial fossa meningioma that have the best evidence base, with practical links to how each factor may influence risk.
Higher body mass index is associated with a higher risk of meningioma. The link appears dose-dependent and may reflect effects of adipose-driven inflammation and sex-steroid signaling.
Lower levels of regular movement are linked with higher meningioma risk in observational studies. Consistent aerobic activity may help lower risk partly through weight control and favorable hormonal and metabolic effects.
Postmenopausal hormone therapy, particularly when it includes progestins and is used long-term, has been associated with increased meningioma risk. Discuss duration and formulation choices with a clinician if therapy is needed.
Prolonged use of high-dose progestin medications has been linked to meningioma development in a duration-dependent way. Risk may diminish after discontinuation, so periodic review of ongoing need is important.
Risk prevention
Preventing an anterior cranial fossa meningioma is not always possible, but you can lower risk and catch concerns early. Prevention is about lowering risk, not eliminating it completely. The biggest levers are limiting avoidable head radiation, being thoughtful about certain hormones, and staying alert to early changes. If you have a higher risk—such as a strong family history or prior radiation to the head—targeted screening may help.
Avoid unnecessary head CTs and other ionizing radiation when safer options like MRI or ultrasound will do. Ask if shielding or alternative tests are appropriate for your situation.
Some high-dose hormone medicines, especially certain progestins, have been linked to meningioma risk and growth. Review birth control, fertility drugs, and menopause therapy with your doctor if anterior cranial fossa meningioma is a concern.
Higher body weight has been associated with a small increase in meningioma risk. Gradual, sustainable changes in food choices and daily movement can help lower that risk over time.
Pay attention to headaches, changes in smell, vision shifts, or personality and memory changes—these can be early symptoms of anterior cranial fossa meningioma. Seek prompt evaluation if new, unexplained symptoms persist or worsen.
Transmission
Anterior cranial fossa meningioma is not contagious and cannot be passed from person to person through contact, coughing, or bodily fluids. In most people, it does not run in families, and there is no genetic transmission of anterior cranial fossa meningioma. Rarely, a higher risk can be inherited as part of certain syndromes, such as neurofibromatosis type 2 (NF2), where a parent can pass down a gene change that raises the chance of meningiomas. Even in these families, the exact location and timing vary, and most meningiomas still arise by chance.
When to test your genes
Because anterior cranial fossa meningiomas are usually not inherited, most people don’t need genetic testing. Consider testing if you were diagnosed at a young age, have multiple meningiomas, a family history of similar tumors, or features suggesting a tumor‑predisposition syndrome (like NF2). Test results can guide surveillance plans, treatment choices, and screening for relatives.
Diagnosis
Subtle changes like more frequent headaches, a dulled sense of smell, or vision changes often prompt the first check-up, which can lead to evaluation for an anterior cranial fossa meningioma. Doctors usually begin with a careful history and exam, then use brain imaging to look for a tumor and its effects on nearby nerves and blood vessels. Your care team will explain how anterior cranial fossa meningioma is diagnosed and which tests you may need. Some diagnoses are clear after a single visit, while others take more time.
Your provider asks about headaches, smell changes, memory or personality shifts, and vision symptoms. Mapping what started first and how it progressed helps target testing.
Doctors check strength, reflexes, balance, and thinking. They also test smell, eye movements, and facial sensation, which can be affected by an anterior cranial fossa meningioma.
An MRI with contrast highlights a dural-based mass and shows its size and exact location. It helps assess pressure on the optic nerves, the pituitary region, and nearby vessels.
A head CT shows bone changes such as thickening or calcifications near the tumor. This helps confirm an anterior cranial fossa meningioma and guides surgical planning.
Stages of Anterior cranial fossa meningioma
Anterior cranial fossa meningioma does not have defined progression stages. Instead, it’s described by tumor grade (how the cells look under the microscope) and by location, and symptoms tend to reflect size and pressure on nearby areas rather than a stepwise stage. Different tests may be suggested to help confirm the diagnosis and plan care. Evaluation usually includes a neurological exam and MRI with contrast; early symptoms of anterior cranial fossa meningioma can be headaches, changes in smell, subtle personality or thinking shifts, or vision issues, and growth is monitored with periodic scans, while surgery or biopsy provides the grade when needed.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially after hearing they have an anterior cranial fossa meningioma. These tumors are usually slow-growing and benign, and many people do well for years with monitoring or surgery. The outlook is not the same for everyone, but factors like tumor size, how close it is to the optic nerves or important blood vessels, and whether it’s causing symptoms help shape next steps.
Prognosis refers to how a condition tends to change or stabilize over time. For anterior cranial fossa meningioma, complete surgical removal often leads to long-term control, with low chances of the tumor returning. When full removal isn’t safe because of nearby structures, partial removal followed by targeted radiation can still offer strong control and preserve vision and cognitive function. Early symptoms of anterior cranial fossa meningioma—such as gradual vision changes, headaches, changes in smell, or subtle memory issues—tend to improve if the tumor is treated before there’s permanent nerve damage.
With ongoing care, many people maintain normal life expectancy, and tumor-related mortality is low, especially for benign (grade 1) tumors. Higher-grade meningiomas are less common in this location but carry a greater risk of coming back and a higher chance of affecting survival, so closer follow-up is important. Looking at the long-term picture can be helpful. Regular MRI checks, protecting vision with timely eye exams, and addressing blood pressure, sleep, and cognitive health can make day-to-day life smoother and support recovery after treatment. Talk with your doctor about what your personal outlook might look like, including the plan for follow-up scans and what changes should prompt a call.
Long-term effects
Day-to-day thinking, mood, and senses can be affected for months or years after an anterior cranial fossa meningioma, whether from the tumor itself or from treatment. Long-term effects vary widely, and not everyone experiences the same changes. While early symptoms of anterior cranial fossa meningioma can be subtle—like a dulled sense of smell or mild forgetfulness—some effects may persist or evolve over time.
Memory lapses, slower processing, and trouble with planning or multitasking can linger. These frontal-lobe effects may ebb and flow with fatigue or stress. They can affect school, work, and day-to-day routines.
Apathy, irritability, or reduced inhibition can appear with frontal brain involvement. Loved ones may notice changes before the individual does. Over time, some traits soften while others remain.
Reduced or absent sense of smell is common with tumors near the olfactory nerves. Taste can seem “off” because smell drives flavor. This may persist even after treatment.
Blurred or dim vision, loss of side vision, or trouble seeing in low light can occur if nearby optic pathways were affected. Some people stabilize after treatment, while others have gradual changes. Regular eye checks may spot shifts early.
How is it to live with Anterior cranial fossa meningioma?
Living with an anterior cranial fossa meningioma can feel like navigating around an unseen weight at the front of the brain, with day-to-day effects that may include headaches, changes in smell, subtle memory or personality shifts, fatigue, and sometimes vision issues. Many people can keep working and caring for family, but they may need more rest, a quieter environment, and help organizing tasks, especially during periods of monitoring, treatment, or recovery. Partners, family, and coworkers often notice changes first and can be vital allies—offering rides to appointments, patience with slower processing or mood changes, and support during follow-up scans. With a care plan that may include watchful MRI monitoring, surgery, or radiation, many regain stability over time, and setting gentle routines, managing stress, and pacing activities can make daily life feel steadier.
Treatment and drugs
Anterior cranial fossa meningioma treatment focuses on safely removing or controlling the tumor while protecting brain function, vision, and sense of smell. For small, slow-growing tumors found by chance, careful monitoring with periodic MRI scans may be all that’s needed; when treatment is required, surgery is usually the first option, often through a minimally invasive approach to lower risks and shorten recovery. If the tumor is hard to reach or close to delicate areas, targeted radiation such as stereotactic radiosurgery can control growth, either as the main treatment or after surgery if a small remnant remains. Medicines that ease symptoms are called supportive therapies, and may include short-term steroids to reduce swelling, anti-seizure drugs if seizures occur, and pain control as needed. Not every treatment works the same way for every person, so your doctor can help weigh the pros and cons of surgery, radiation, and observation based on tumor size, location, growth rate, your age, and overall health.
Non-drug treatment
Non-drug treatments for anterior cranial fossa meningioma focus on preserving thinking, vision, and daily independence while controlling the tumor. Non-drug treatments often lay the foundation for recovery and long-term quality of life. Choices depend on tumor size, growth rate, and which brain areas are under pressure. Plans are individualized and may combine careful monitoring, surgery or radiation, and rehabilitation.
Regular MRI scans track growth and guide timing of treatment. Clinicians also watch for early symptoms of anterior cranial fossa meningioma, like subtle personality change or reduced sense of smell. This option suits small, slow-growing tumors without worrisome pressure.
Neurosurgeons remove as much tumor as safely possible to relieve pressure on the frontal lobes and optic nerves. Modern techniques and navigation aim to protect memory, vision, and smell. Hospital recovery is followed by tailored rehab.
Some tumors can be removed through the nose using an endoscope, avoiding large scalp incisions. This approach may shorten recovery and lower infection risk. Not all anterior cranial fossa meningiomas are suited to this route.
Focused radiation (such as Gamma Knife) targets the tumor in one or a few sessions. It can control growth for anterior cranial fossa meningioma when surgery is risky or after partial removal. Eye and brain structures are carefully shielded.
Your genes may have an impact on how drugs work for you
Even with the same tumor, people can process pain medicines, anti-seizure drugs, or steroids differently because enzyme genes act like dimmer switches, speeding or slowing drug breakdown. Knowing your genetic profile can guide safer doses and avoid side effects.
Pharmacological treatments
Medicines for anterior cranial fossa meningioma mainly ease symptoms or support care around surgery and radiation; they rarely shrink the tumor itself. Drugs that target symptoms directly are called symptomatic treatments. For many, this can mean reducing swelling, preventing seizures, or managing pain and nausea. Medicines won’t erase early symptoms of anterior cranial fossa meningioma that came from pressure on nearby brain structures, but they can make daily life more manageable while definitive treatments are planned.
Dexamethasone can reduce brain swelling that causes headache, confusion, or vision changes. It’s usually used short-term and tapered to lower risks like high blood sugar, sleep changes, and infection.
Levetiracetam is commonly used to prevent or control seizures; lamotrigine is another option. Dosing may be increased or lowered gradually to balance seizure control with side effects like dizziness or fatigue.
Acetaminophen often helps headaches, and NSAIDs like ibuprofen or naproxen can be used if your care team says they’re safe. NSAIDs may be paused before surgery because they can increase bleeding risk.
Ondansetron can ease nausea from raised pressure or from other medicines. This can help you stay hydrated and keep up with meals.
Genetic influences
People often ask whether anterior cranial fossa meningioma is hereditary. It’s natural to ask whether family history plays a role. For most people, this tumor does not run in families; it usually develops because of gene changes that arise only in the tumor cells over time, not ones you were born with. Rarely, an inherited condition such as neurofibromatosis type 2 (NF2) raises the chance of meningiomas, sometimes at a younger age and sometimes more than one. Tumors at the front of the skull base more often have these “acquired” changes rather than inherited ones, and their genetic patterns can differ from meningiomas on the brain’s outer surface. Even with an inherited risk, it doesn’t mean a tumor will definitely develop—only that the odds are higher. If several relatives have meningioma, if it’s diagnosed early, or if there are related features such as hearing-nerve tumors, asking about genetic counseling and possible testing may help clarify risk for you and your family.
Is Anterior cranial fossa meningioma genetic?
Genetics play a modest role in anterior cranial fossa meningioma overall, but certain inherited syndromes, like neurofibromatosis type 2, raise risk. Tumor DNA changes—often NF2 or other pathway alterations—can guide prognosis and, sometimes, targeted therapy choices.
Pharmacogenetics—how genetics influence drug effects
For anterior cranial fossa meningioma, genetics can shape treatment choices after surgery or when disease returns, especially if medicines or clinical trials are being considered. Testing the tumor may find changes in genes such as SMO or AKT1 (common in many skull‑base tumors) that point to targeted options—such as medicines that block the SMO‑driven growth signal or therapies aimed at the AKT–mTOR pathway. Many of these tumors also carry somatostatin receptors, which is why some teams use somatostatin‑based drugs or targeted radiation that delivers a small dose directly to receptor‑bearing cells. On the personal side, differences in liver enzyme and drug‑transporter genes can affect how your body handles medicines sometimes used for meningioma, including everolimus and sunitinib, which may change the risk of side effects or how well a drug works. Pharmacogenetic testing doesn’t give a “yes or no” answer, but it can help estimate the chance of side effects or under‑dosing and may guide dose choices alongside blood‑level monitoring. Genes are only part of the picture; age, other medications, and kidney or liver health also matter, so doctors combine genetic results with imaging and pathology to tailor targeted therapy for anterior cranial fossa meningioma.
Interactions with other conditions
People already living with migraines or a seizure disorder may notice these problems intensify when an anterior cranial fossa meningioma is present. In this setting, a condition may “exacerbate” (make worse) symptoms of another, so headaches can linger, and a previously well‑controlled seizure pattern may change. Because this tumor sits near the frontal lobes and the sense-of-smell pathways, early symptoms of anterior cranial fossa meningioma—such as subtle memory lapses, personality shifts, or reduced smell—can be mistaken for depression, anxiety, or early dementia, and these conditions can also amplify each other’s effects. Nasal allergies or chronic sinus issues can further blur the picture by causing congestion and smell loss that resemble tumor-related symptoms.
Heart and blood vessel diseases matter, too. People taking blood thinners for atrial fibrillation, a prior clot, or a mechanical valve generally need careful planning before any brain surgery, and certain pain or sleep medicines may interact with anti-seizure drugs. A history of neurofibromatosis type 2 (NF2) raises the chance of having more than one meningioma, which can change follow-up plans and treatment timing. Close, coordinated care helps sort out which symptoms stem from the tumor versus another condition and guides a safer, more streamlined treatment path.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described headaches, personality shifts, and changes in smell or vision that likely trace back to slow-growing tumors at the front of the skull. Families and communities once noticed patterns—an aunt who became more forgetful and less organized over years, a neighbor whose sense of smell faded and who developed persistent pressure behind the eyes—long before imaging could show what was happening. These were early echoes of what we now recognize as anterior cranial fossa meningioma.
First described in the medical literature as firm, surface tumors arising from the brain’s coverings, these growths were initially understood through symptoms and surgery alone. Before X‑rays and CT scans, surgeons relied on careful neurological exams and clues like gradual behavior change or a new visual blind spot to guess the tumor’s location. Operations were risky, and many tumors in this region were found only during surgery or at autopsy, shaping early, incomplete pictures of the condition.
As medical science evolved, the story changed. The introduction of pneumoencephalography and angiography in the early to mid‑1900s gave indirect outlines of tumors pressing on the frontal lobes or the nerves behind the eyes. CT scanning in the 1970s, and especially MRI in the 1980s and 1990s, allowed doctors to see anterior cranial fossa meningiomas in much greater detail: their size, their relationship to smell pathways and eye nerves, and whether they touched nearby blood vessels. From these first observations to modern imaging, safer and more precise surgery followed, including approaches through the eyebrow or the base of the skull designed to protect vision and memory.
Radiation therapy also advanced. Earlier broad-beam methods gave way to focused techniques like stereotactic radiosurgery, which could target small or residual tumors while sparing healthy brain tissue. At the same time, pathology refined how these tumors are classified, separating the most common, slow-growing type from the less common, faster-growing forms. This helped clinicians better estimate behavior over time and plan follow-up.
Genetic insights arrived more recently. Researchers found that many meningiomas, including those in the anterior cranial fossa, often carry changes in genes that act like on/off switches for cell growth. These discoveries do not replace imaging or pathology, but they help explain why some tumors grow very slowly while others are more active, and they are guiding studies of new, targeted treatments.
In recent decades, knowledge has built on a long tradition of observation. Today, anterior cranial fossa meningioma is usually found earlier—sometimes by chance during a scan for headaches or after a mild head injury—and managed with a mix of careful monitoring, focused radiation, or surgery when needed. Looking back helps explain why early descriptions emphasized personality and vision changes, and it highlights how each step, from bedside observation to MRI and genetics, has improved safety, outcomes, and quality of life for people living with this tumor.